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Abstract
Introduction: Chronic migraine is a largely refractory condition affecting between 1 and 2.2% of the overall population
worldwide, with females more affected than males. There are also high health and socioeconomic costs associated both
for the individual and society. The mainstay of chronic migraine management is pharmacological, but the options
available have limited efficacy and there are often unwanted side effects. There is some evidence for manual
therapy as a treatment option for migraine, but its effectiveness for chronic migraine is unknown. Therefore,
we have designed a pragmatic randomised control trial to investigate whether adding manual therapy to the
tertiary specialist treatment of chronic migraine improves patient-reported outcomes.
Methods: A pragmatic, randomised controlled trial in a hospital tertiary headache clinic. Participants will be
randomised into one of two groups: treatment as usual or treatment as usual plus manual therapy. The primary
outcome measure will be a change in the Headache Impact Test score. Secondary outcomes will also be measured
over the 12-week study period including changes in headache frequency, migraine specific quality of life and
reductions in relevant medicine consumption. The manual therapy group will have five treatment sessions
each lasting 30 min. The recruitment target of 64 participants will allow power at 80% with p = 0.05 using
minimal clinical difference for Headache Impact Test of 3.7 and includes provision for a 10% dropout rate.
Recruitment will take place between August 2018 and February 2019. The results will form part of a doctoral
study and be published in peer-reviewed journals and presented at national/international conferences.
Discussion: Current pharmacological approaches have limited effects in the management of chronic migraine
and there is a requirement to improve treatment options and reduce the health and economic burden of the
condition. Manual therapy has been shown to be effective in other chronic pain conditions as well as other
primary headaches. This study will explore the effectiveness of manual therapy as an adjunctive approach to
the management of chronic migraine.
Trial registration: The trial has received a favourable opinion from the UK Health Research Authority (IRAS 228901)
and is registered at ClinicalTrials.gov.number NCT03395457. Registered 1st March 2018.
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Background
Migraine is experienced by the vast majority of sufferers
as episodic migraine (EM) [1, 2] occurring regularly al-
though not necessarily frequently, with around 65% of
sufferers estimated to have a migraine episode fort-
nightly to monthly [3]. However if the episodic pattern
becomes uncontrolled, a process of chronification occurs
whereby the original episodic migraine becomes very
frequent and more disabling. This is termed chronic
migraine (CM) and is described by the International
Headache Society (IHS) classifications [4] as “headache
occurring on 15 or more days per month for more than
three months, which, on at least 8 days per month, has
the features of migraine headache”. On the days without
migraine headache the individual can often suffer from
pre and post headache effects adding to the burden of
this condition.
The management of CM is more complex than EM, as
it is often resistant to standard treatments with resultant
additional costs compared to EM. The mean (SD) an-
nual cost per CM person ($8243 [$10,646]) was over
three times that of those with EM ($2649 [$4634]). Both
direct medical costs and cost of lost productivity were
substantially higher in CM than EM [5]. In addition to
financial costs, the social costs and personal impact of
CM often leads to severe disability for those with CM [6,
7]. This is especially true for females, with the annual
prevalence of CM in women being 1.7–4.0% compared
to men (0.6–0.7%) [8–11]. Those women aged between
18 and 49 years of age are the most affected across the
range of measures. In one study, CM sufferers were
found to be three times more likely to have lost work
and have reduced household productivity than those
with EM (58% compared to 18%) [12]. People with CM
are also much more likely to report “very severe
headache-related disability” as measured by the Migraine
Disability Assessment Scale (MIDAS) than those with
episodic (24.8 and 3.2% respectively) [13, 14].
Despite the suggestion that migraine is a syndrome
with multiple pathological mechanisms which support a
multi therapeutic approach rather than a single ap-
proach [15–17], the mainstay of treatment for CM is
pharmacological. However, some patients do not want,
or cannot, take some prophylactic medications such as
Topiramate due to restrictions in its use [18]. Currently,
OnabotulinumtoxinA (Botox) is the only specifically li-
censed treatment for CM in the UK [19]. Although its
mechanism of action is unclear, studies have demon-
strated that injecting specific sites on the head and neck
produce significantly beneficial effects in CM patients.
One study concluded that 32% of CM patients achieved
a 50% reduction in headache days and a 50% reduction
in migraine days, with NICE guidance recommending a
30% reduction in headache days as a measure of success
in Botox studies [20]. Although similar clinically signifi-
cant reductions in the Headache Impact Test (HIT 6)
scores are seen with Botox and Topiramate interven-
tions, Botox has fewer side effects and higher adherence
rates [21, 22]. However, the efficacy of Botox in those
patients who benefit only partially or not at all from
Botox, and its relatively high cost, are barriers to an in-
creased uptake [23–25]. Therefore if adjunctive therap-
ies, especially those with fewer side effects and relatively
low costs could be utilised, this may increase the benefit
to more of those with CM.
One possible adjunctive intervention is manual ther-
apy. Despite the mechanisms of its potential action in
CM being unknown, the basis for its potential role can
be garnered from studies in associated conditions. These
include primary headaches (tension type and migraine),
as well as common comorbidities; chronic pain and spe-
cifically neck pain. One systematic review concluded that
MT has an efficacy in the treatment of chronic tension
headache equal to that of prophylactic medication with
tricyclic antidepressant [26]. Another involving massage
therapy and chiropractic spinal manipulative therapy
concluded that they may be as efficient as Propranolol
and Topiramate in migraine prophylaxis. It also con-
cluded that there is moderate quality evidence for both
spinal manipulation and mobilisation as suitable treat-
ments in chronic non-specific neck pain [27]. These
studies found benefits in at least one of the following:
frequency, duration and intensity of headaches/pain.
Currently there are two theories in existence relevant
to this study of manual therapy in the management of
chronic migraine. One is that migraine is, in part, an ab-
normal response in those genetically pre-disposed, to
nociceptive input involving the nerves of the upper cer-
vical spine (C1, C2 and C3) and associated joints and
muscles. This leads to exaggerated sensitisation of the
trigeminal pathway and subsequent face, neck and head
pain [28–30].
The other theory incorporates the allostatic model in
which people respond to stressful events, actual or per-
ceived, with physiological and behavioural changes. In
general these changes maintain normal physiological sta-
bility (allostasis). However, if stressors (including on-
going pain or nociceptive inputs) become too great or
frequent then the normal response can become dysfunc-
tional as a result of allostatic loading, which itself alters
brain structure and function. Likewise, repeated mi-
graines are themselves thought to be a driver of changes
to the brain structure that may lead to a dysfunctional
allostatic response. Consequently, many migraine suf-
ferers report that stressful activities of daily living (phys-
ical and emotional) exacerbate their migraines [31, 32].
Chronification from EM to CM may be a result of the
stress mechanisms generating the migraine or as a
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consequence of changes in the brain arising in response
to the attacks. Therefore if stressors (for example noci-
ceptive pain, and central sensitisation, possibly from
musculoskeletal disorders) can be reduced, this may add
to the efficacy of existing interventions [33].
Whilst the process of chronification in CM is not fully
understood, there are a number of known associated risk
factors including head and neck injury, and other pain
disorders [34] (Table 1).
Currently, one of the most common factors in chroni-
fication is considered to be the presence of medication
over use headaches (MoH) due to the frequent use of
opioids and barbituates in self medication of headaches,
or in association with concomitant conditions. Estimates
of between 30 and 72% of CM patients presenting at ter-
tiary clinics are thought to have MoH associated chroni-
fication [35, 36]. The IHS diagnosis of medication
overuse is made if abortive drugs are used regularly for
more than three months on 10 or more, or 15 or more,
days a month, depending on the drug. One study esti-
mated a twofold increase in chronification with opioid
use on 8 days a month [37]. Therefore any studies of in-
terventions in CM should include a detoxification phase
or a process to mitigate CM with MoH being included.
Both of the above migraine models suggest a role for
altered sensory processing in the brainstem, which is as-
sociated with the presence of central sensitisation and
one of the consequences, cutaneous allodynia (CA).
Some studies cite CA as more prevalent in CM than
EM, whilst others suggest there is little difference and it
is more a reflection of migraine duration. There are a
few potential reasons for these differences which include:
the type of CA – thermal, dynamic and static mechan-
ical; how it is measured and the temporal nature of CA
making it difficult to measure consistently; and its role
as a marker for the risk of frequent attacks rather than
simply a consequence of frequent attacks [38, 39]. CA is
also consistently reported more in females than males
(49.7% vs 32.6%%, P < 0.001) [40] and is common in
other chronic pain conditions, with its presence associ-
ated with a reduction in the efficacy of abortive treat-
ments [41, 42].
Various models of MT and pain reduction exist which
involve biomechanical, neurophysiological and psycho-
logical components, either individually or in combin-
ation. However all of these models consider that MT
may work by activating descending inhibitory pathways
via different levels of the spinal cord [43–45]. The com-
mon relationship of central sensitisation, the cervical
spine, and pain disorders (see Table 1) would suggest
MT may have utility in the management of CM.
In terms of potential as an adjunctive treatment, MT
has been shown to reduce pain and have a direct effect
on the mechanics of the cervical spine that results in
functional improvements [46–48]. MT has also been
shown to increase local pain pressure thresholds, which
are used to detect central sensitisation [49, 50]. Conse-
quently, MT may reduce cutaneous allodynia and im-
prove the efficacy of current approaches to treating CM.
The above discussion outlines commonalities between
migraine, other pain conditions, its chronification and
the potential for MT in its treatment. Combined with
evidence showing the scope for improvement in existing
CM treatment, this suggests there may be potential for
the use of adjunctive non-pharmacological treatments,
especially if these are generally associated with lesser
side effects [16, 51].
The objective of this study is to determine the effect-
iveness of MT as an adjunctive therapy to tertiary care
(‘care as usual)’ in CM.
Methods
Study design
This will be a single centre, pragmatic Randomised Con-
trolled Trial (RCT) involving 64 participants. The two
groups will be “Tertiary care as usual” and “Tertiary care
as usual plus MT”. The objective of the study is to meas-
ure the difference between the two treatment groups in
CM. The study design adheres to the IHS and Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines [52, 53]. The study flow is outlined in Fig. 1.
Participants
Recruitment
Participants will be recruited between August 2018 and
February 2019 through the Salford Royal NHS Founda-
tion Trust acute neurology clinic service in the UK. The
neurologist and specialist headache nurse will identify
Table 1 Risk factors associated with migraine chronification and
reversion
• Obesity
• Snoring
• Sleep disorders
• Excessive caffeine intake
• Psychiatric/psychological disease (Depression/Anxiety)
• High baseline headache frequency
• Overuse of migraine abortive drugs
• Major life changes
• Head or neck injury
• Cutaneous allodynia
• Female sex
• Comorbid pain disorders
• Lower socioeconomic status
(Adapted from Schwedt, 2014, [79])
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Fig. 1 Participant flow
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potential participants from their list of existing CM
patients.
Details of this study will be sent to potential partici-
pants with their clinic appointment letter. Eligible partic-
ipants will be female aged greater than 18 years of age,
and diagnosed with CM according to the criteria of the
International Classification of Headache Disorders (ICH-
D-III) by their neurologist. The enrolment in to tertiary
care requires that patients must be free of medication
over use headache and as part of the inclusion criteria
(Table 2), participants will have gone through a detoxifi-
cation phase and had at least one cycle of tertiary care
treatment to further mitigate medication overuse head-
ache. Exclusion criteria for this study are: contraindica-
tion to MT including spinal radiculopathy; uncontrolled
psychological conditions; and any physical or MT in the
last 6 weeks. Acute and abortive migraine medication
will continue as usual during the study.
Inclusion and exclusion criteria
Sample size
The study is powered at 80% (α =0.05) to detect a mean
difference of 3.7 points in HIT6 before and after treat-
ment. A pooled calculation of standard deviation (SD) of
4.91 was calculated for the Headache Impact Test
(HIT6) from the analysis of major studies in chronic mi-
graine [7, 54–59]. Although this requires 29 participants
in each group, 32 will be recruited to allow for attrition
that may be experienced over a 12 week period.
Allocation
A randomisation assignment sequence will be created by
an independent member of the research team using ran-
domisation software “Research Randomizer” [60]. The
results will be put into sealed opaque envelopes which
the participants will open in their meeting with the PI,
who will explain the process to be followed depending
on the group allocation.
Immediately following the initial screening by the
neurologist/specialist nurse, those participants who meet
the inclusion criteria will be invited to an assessment
with the Principal Investigator (PI). If this is not possible,
it will be arranged within 5 days. The PI will provide par-
ticipants with verbal and written information about the
project before gaining written consent. He will also ex-
plain the risks, and benefits as well as the potential ad-
verse reactions to MT and how to manage them.
Potential adverse reactions may include temporary local
tenderness, aching and tiredness [61]. Participants will
be randomised into two groups (care as usual and care
as usual plus MT).
The neurologist will be blinded as to the participant’s
group allocation in order to reduce initial selection and
potential contact bias. The PI cannot be blind to the
manual therapy group but will be blinded to the end of
study survey analysis, with an independent member of
the research team detailed to recode the participant ref-
erence numbers and store the key file on a password
protected computer. The unblinding of single cases by
the PI/CI in the course of a clinical trial will only be per-
formed if necessary for the safety of the trial subject.
Intervention
The neurologist will manage the care as usual group
alone. The care as usual and MT group will be managed
by the neurologist and receive MT from the PI. The MT
administered will consist solely of mobilisation, manipu-
lation and soft tissue work. The PI will use a pragmatic
approach to the MT administered, using any of the
above manual interventions deemed clinically appropri-
ate at each appointment based on assessment prior to
treatment and participant feedback. The PI is an experi-
enced chiropractor with over ten years’ clinical
experience of chiropractic and soft tissue work, with
postgraduate education and training in the management
of CM. The treatment delivered will be recorded in the
Case Report File (CRF). Failure to attend all manual
therapy sessions will result in withdrawal from the study
although provision will be made to provide an alternative
Table 2 Inclusion and exclusion criteria
Inclusion Criteria
• Females over 18 years of age
• A good command of English (to enable informed consent)
• Existing patients with chronic migraine as diagnosed by a clinical
interview with a neurologist in line with the International Classification
of Headache Diagnosis criteria (ICHD)
• Undergoing care as usual from the neurologist
• Must have had at least one cycle of treatment from neurologist and
not be a new patient
Exclusion Criteria
• Currently having or had manual therapy to the neck or shoulder in the
previous six weeks.
• A new patient without any existing management by neurologist
• Having a condition contraindicated for manual therapy including, but
not limited to, inflammatory disorders, severe osteoporosis and tumours.
• Identification of any medical ‘red flags’ by the neurologist.
• Evidence of any central nervous system involvement for example:
o Facial palsy (presence of ptosis/Horner’s syndrome)
o Visual disturbance (presence of blurred vision, diplopia, hemianopia)
o Speech disturbance (presence of dysarthria, dysphonia, dysphasia
such as expressive or receptive)
o Balance disturbance (presence of dizziness, imbalance, unsteadiness, falls)
o Paraesthesia (presence, location such as upper limb/lower limb, face)
o Weakness (presence, location such as upper limb/lower limb)
o Known major psychiatric or psychological conditions not under control
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appointment if the participant cannot make one as
planned. Any change in a participant’s medical condition
such that they fulfil the exclusion criteria above will result
in their withdrawal from the study. Data from these par-
ticipants would not be included in the final study results.
Adverse events will be recorded in the CRF, and if classed
as serious would be referred to the neurologist to be re-
ported to the sponsor within 24 h of learning of the event
and to the Main Regional Ethics Committee within 15
days in line with the required timeframe. The outline
interventional procedure is shown in Table 3 with the pro-
ject flow following the SPIRIT guidelines (Table 4).
Outcome measures
The primary and secondary endpoints are differences in
within-group changes between groups in the outcomes
listed below (Table 5). These will be measured using the
weekly diaries and the validated instruments in the base-
line and 12-week follow-up questionnaires.
Data collection
All participants will be asked to complete a baseline
questionnaire, comprising demographic information and
the following validated instruments: Headache Impact
Test (HIT6), the Migraine Specific Quality of Life Ques-
tionnaire (MSQ.V2),The perceived Stress Scale (PSS-10),
State and Trait Anxiety Inventory (STAI-6),Brief Cope,
Hospital Anxiety and Depression Scales (HADS) and the
12 Item Allodynia Symptom Checklist (ASC-12) The
questionnaire will be available in paper or online format
for completion at the initial assessment or at home at
the discretion of the participant.
BMI values (from height and weight) will be calculated
in the clinic and pain pressure thresholds will be taken
using a somedic electronic pressure algometer [62] on
each of the following muscles: Frontalis, Trapezius and
Subocciptal. The order of these measurements will be
taken randomly, which is an approach used in previous
migraine studies [47, 48]. A distal site (forearm) will also
be included to help provide a measure of wide spread
central sensitisation [63]. These measures will be taken
again at the end of the study after 12 weeks. Individuals
assigned to the tertiary care as usual plus MT group will
be given a 12 week treatment plan as recommended in
IHS guidelines [52]. Sessions will be planned for Weeks
1, 2, 5, 8 and 12.The care as usual group will complete
the normal 12 week cycle with the neurologist. Both
groups will complete weekly diaries and an end of study
questionnaire that duplicates the baseline questionnaire
and includes a Patient Global Impression of Change
Scale.
To encourage completion of data the participants will
be encouraged to complete paper versions of the ques-
tionnaire at the first visit in the waiting area and leave it
at reception, rather than taking home. Online versions
will also be available. Reminder text message or emails
will be sent out each week to encourage completion of
the paper or online weekly diary.
Data management
The questionnaires and diaries will not contain informa-
tion that can identify individuals, only an individual ref-
erence number. All information used for this research
will be kept securely on password protected computers
and only accessible by members of the research team.
Any data that can identify a participant will be destroyed
within 3 months of final data collection. Anonymous
data may be kept for up to 5 years on a secure university
computer.
Statistical analysis
Descriptive demographic and clinical characteristics will
be collected, using means and SDs for continuous vari-
ables and proportions and percentages for nominal
variables. Each group will be described separately. Quan-
titative data collected from each group will be analysed
using SPSS (™) Version 24 software. Parametric tests
will be used to analyse data wherever it is normally
distributed, and non-parametric will be utilised for
non-normal data.
The mean and standard deviations of primary and sec-
ondary outcomes will be reported, with an analysis of
between- group differences over the 12 weeks using
Students T test or Mann-Whitney. The effect size will
be calculated using the following figures: small (0.2–0.5),
medium (0.5–0.8) or large (> 0.8). Repeated measures
ANOVA will be used to explore the differences between
intermediate time points. If appropriate, multivariate lin-
ear regression (MANOVA) will assess the secondary
outcome relationship with changes in primary outcomes.
Table 3 Manual therapy protocol
1. Assess upper bodya posture in sitting
2. Assess active and passive neck range of motion
3. Assess shoulder girdle range of motion by raising each arm sideways
from side of body up to ear
4. Assess the temporomandibular joint
5. Identify areas to treat in sitting position
6. Administer MT using mobilisation, manipulation and soft tissue release
in sitting position
7. Assess patient shoulder girdle, neck and head supine and prone
8. Administer MT in supine and prone position
9. Following each session an outline of the MT used will be recorded.
10. A total of 30 min will be allocated for each participant at these
consultations
aUpper body defined as from thoraco-lumbar junction upwards
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Correlation between primary and secondary outcomes
will use Pearson’s coefficient.
Discussion
Two high quality RCTs have explored the effectiveness
of MT in those with migraine, of which only one study
specifically reported on those with a diagnosis of CM
[64, 65]. This was a 3-Armed RCT with 105 participants
using osteopathy (MT) and medical therapy, sham and
medical therapy and medical therapy alone. The results
were a reduction in HIT-6 score by an average of− 8.74;
p < 0.001 with OMT compared to medication care as
Table 4 Project Flow Manual Therapy for Chronic Migraine
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usual. There were also statistically significant (p < 0.001)
reductions in medication use and migraine frequency. In
comparison, this study will use only one practitioner in-
stead of six, and five sessions over three months instead
of eight sessions over six months. The technique used
will be chiropractic rather than osteopathy, although
similar soft tissue release and mobilisation techniques
will be used (albeit on a broader area of the shoulder gir-
dle and neck). This difference with a crossover of simi-
larity should strengthen the theory that manual therapy
of different types can produce similar adjunctive benefits
and add to the dose benefit discussion.
There is evidence to suggest that MT as an adjunct to
Botox improves outcomes in those with CM. This comes
from a pilot study with 22 participants [66]; one group
had transcutaneous electrical nerve stimulation (TENS)
and Botox, the other MT and Botox. Each group had
one 30 min session per week over 4 weeks. Both groups
showed a reduction in medication use and pain pressure
thresholds in the MT group compared to the TENS. This
study aims to build on the outcomes of previous studies
focussing on MT as an adjunctive therapy to ‘usual care’
for those receiving treatment in a tertiary care setting.
At the time of writing, this study is thought to be the
first to measure central sensitisation using algometry in
CM whilst tracking changes using the Allodynia Symp-
tom Checklist. This will allow greater understanding of
potential temporal changes in central sensitisation with
treatment outcomes. It should also provide a compari-
son between the baseline and final algometry changes
and the Allodynia Symptom Checklist measures.
Methodological considerations
The study is designed to be pragmatic and to balance
the needs of efficacy and effectiveness in clinical re-
search [67]. The HIT 6 score is used in this study as the
primary outcome measure, as this is the only headache
disability measurement tool with established validity in
CM [54, 57]. The number of headache/migraine days
will be collected as a secondary measure using a head-
ache diary, a well established and valid measurement in-
strument [68–70] and recommended by the IHS.
Blinding and the placebo effects are potential limita-
tions in this study. Although it is impossible to blind the
PI for treatment, the final results will be re-coded to re-
duce the potential for analysis bias. The placebo effect is
known to be high in all headache studies with acute
treatment placebo being higher than prophylactic and
tablets lower than injection [71, 72]. In studies of botox
in chronic migraine, both in the immediate 12 week cycle
and in longer term studies over multiple cycles, au-
thors have cited placebo levels of between 20 and
49% [73, 74].
It is recognised that the MT group may experience a
higher level of placebo as a result of the necessary inter-
personal interactions [75, 76]. However in this study
there is a high level of personal interaction with the
headache nurse who applies the medical interventions
and thus may be considered a balancing to interactions
in the MT sessions.
The external validity of the RCT may be a weakened
as a result of the involvement of only one manual ther-
apist, and thus could limit the measure of consistency of
outcomes across different practitioners. Conversely, this
will reduce the risk of potential multiple bias that comes
with the use of multiple therapists. To mitigate reduc-
tions in external validity, the study focuses on a specific
group in a ‘real life setting’ (females aged 18 years and
above with CM in tertiary clinics) [77]. It will measure
factors including stress, depression, coping styles, anx-
iety, diet, sleep quality, and allodynia, all of which poten-
tially affect the primary and secondary outcomes.
Although the IHS recommend a placebo control for
prophylactic pharmacological studies, there is evidence
that less than 10% actually conform [78] and likewise
despite having two active arms this study also lacks a
placebo control group. To address this limitation, and in
the absence of IHS guidelines for non-pharmacological
trials, the study design will adhere closely to the recom-
mendations for IHS pharmacological RCTs in chronic mi-
graine. The CONSORT guideline for non-pharmacological
studies will be followed which provides a systematic
Table 5 Outcome Measures
Primary Outcomes Measurement Instrument (validity)
Migraine-related disability Headache Impact Test (HIT 6) [54]
Secondary Outcomes Measurement Instrument
Quality of Life Migraine Specific Quality of Life
Questionnaire (MSQ. V2.1)[59]
Use of abortive migraine medications 1.1.11.1.11.1.1Diary [69]
Percentage of participants with
reduction in headache frequency
(days per month) of greater than 50%
Number of headache free days
Stress
Stress Perceived Stress Questionnaire
(PSS) [80]
Stress Brief Cope [81]
Anxiety State and Trait Anxiety Inventory
(STAI-6) [63]
Anxiety & Depression Hospital Anxiety and Depression
Scale (HADS) [82]
Cutaneous Allodynia Allodynia Symptom Checklist
(ASC) [83]
Cutaneous Allodynia Algometry [49, 84]
Patient Reported Outcome
Measure
Patient Global Impression of
Change Scale (PGICS) [85]
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approach to ensuring quality and the external and internal
validity of clinical studies.
Scientific value
CM is a highly disabling condition with few evidence-
based treatment options. In the UK, Botox is the only
specifically approved pharmacological intervention, al-
though Topiramate and occipital nerve injections are
used in tertiary clinics. This study will aim to explore
the outcomes of MT as an adjunct to those receiving
‘care as usual’ for CM in a tertiary setting. It will also
provide information relating to central sensitisation in
the form of CA for participants, which will contribute to
a body of knowledge in those with CM and support tai-
loring treatment options.
Although this will be a pragmatic study, the results of
this study will only be applicable to the target group - fe-
males over 18 years of age with CM under tertiary care.
The approach used will however be generalisable to all
manual therapists with the requisite training in techniques
used. Undertaking the study in a specialist medical head-
ache clinic should help to build the nascent relationship
between medical headache specialists and manual thera-
pists. Post study dissemination will potentially help the de-
velopment of more multidisciplinary approaches.
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HRA guidelines.
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